Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: DNAJC1

Gene summary for DNAJC1

Gene summary.

Gene information	Species	Human
	Gene symbol	DNAJC1
	Gene ID	64215
	Gene name	DnaJ heat shock protein family (Hsp40) member C1
	Gene Alias	DNAJL1
	Cytomap	10p12.31
	Gene Type	protein-coding
	GO ID	GO:0006412
	UniProtAcc	Q96KC8

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
64215	DNAJC1	P17T-E	Human	Esophagus	ESCC	3.50e-12	5.96e-01	0.1278
64215	DNAJC1	P19T-E	Human	Esophagus	ESCC	1.57e-12	9.39e-01	0.1662
64215	DNAJC1	P20T-E	Human	Esophagus	ESCC	2.55e-13	4.24e-01	0.1124
64215	DNAJC1	P21T-E	Human	Esophagus	ESCC	6.15e-42	8.07e-01	0.1617
64215	DNAJC1	P22T-E	Human	Esophagus	ESCC	7.96e-25	3.60e-01	0.1236
64215	DNAJC1	P23T-E	Human	Esophagus	ESCC	4.54e-29	8.06e-01	0.108
64215	DNAJC1	P24T-E	Human	Esophagus	ESCC	7.65e-33	6.92e-01	0.1287
64215	DNAJC1	P26T-E	Human	Esophagus	ESCC	3.31e-50	8.54e-01	0.1276
64215	DNAJC1	P27T-E	Human	Esophagus	ESCC	1.49e-32	5.87e-01	0.1055
64215	DNAJC1	P28T-E	Human	Esophagus	ESCC	1.40e-12	2.66e-01	0.1149
64215	DNAJC1	P30T-E	Human	Esophagus	ESCC	2.39e-05	5.42e-01	0.137
64215	DNAJC1	P31T-E	Human	Esophagus	ESCC	2.30e-18	3.66e-01	0.1251
64215	DNAJC1	P32T-E	Human	Esophagus	ESCC	3.14e-54	1.13e+00	0.1666
64215	DNAJC1	P36T-E	Human	Esophagus	ESCC	1.29e-15	7.53e-01	0.1187
64215	DNAJC1	P37T-E	Human	Esophagus	ESCC	5.83e-31	7.92e-01	0.1371
64215	DNAJC1	P38T-E	Human	Esophagus	ESCC	1.75e-07	3.18e-01	0.127
64215	DNAJC1	P39T-E	Human	Esophagus	ESCC	7.31e-17	2.24e-01	0.0894
64215	DNAJC1	P40T-E	Human	Esophagus	ESCC	4.97e-16	4.44e-01	0.109
64215	DNAJC1	P42T-E	Human	Esophagus	ESCC	1.05e-12	4.32e-01	0.1175
64215	DNAJC1	P44T-E	Human	Esophagus	ESCC	4.75e-17	6.57e-01	0.1096

Page: 1 2 3 4 5 6 7 8 9 10 11

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Breast		IDC: Invasive ductal carcinoma
		DCIS: Ductal carcinoma in situ
		Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers
Colorectum (GSE201348)		FAP: Familial adenomatous polyposis
		CRC: Colorectal cancer
Colorectum (HTA11)		AD: Adenomas
		SER: Sessile serrated lesions
		MSI-H: Microsatellite-high colorectal cancer
		MSS: Microsatellite stable colorectal cancer
Esophagus		ESCC: Esophageal squamous cell carcinoma
		HGIN: High-grade intraepithelial neoplasias
		LGIN: Low-grade intraepithelial neoplasias
GC		CAG: Chronic atrophic gastritis
		CAG with IM: Chronic atrophic gastritis with intestinal metaplasia
		CSG: Chronic superficial gastritis
		GC: Gastric cancer
		SIM: Severe intestinal metaplasia
		WIM: Wild intestinal metaplasia
Liver		HCC: Hepatocellular carcinoma
		NAFLD: Non-alcoholic fatty liver disease
Lung		AAH: Atypical adenomatous hyperplasia
		AIS: Adenocarcinoma in situ
		IAC: Invasive lung adenocarcinoma
		MIA: Minimally invasive adenocarcinoma
Oral Cavity		EOLP: Erosive Oral lichen planus
		LP: leukoplakia
		NEOLP: Non-erosive oral lichen planus
		OSCC: Oral squamous cell carcinoma
Prostate		BPH: Benign Prostatic Hyperplasia
Skin		AK: Actinic keratosis
		cSCC: Cutaneous squamous cell carcinoma
		SCCIS:squamous cell carcinoma in situ
Thyroid		ATC: Anaplastic thyroid cancer
		HT: Hashimoto's thyroiditis
		PTC: Papillary thyroid cancer

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:004586114	Breast	IDC	negative regulation of proteolysis	70/1434	351/18723	8.21e-14	2.22e-11	70
GO:000645713	Breast	IDC	protein folding	47/1434	212/18723	2.31e-11	3.86e-09	47
GO:000641714	Breast	IDC	regulation of translation	74/1434	468/18723	1.67e-09	1.53e-07	74
GO:005070812	Breast	IDC	regulation of protein secretion	36/1434	268/18723	6.93e-04	8.50e-03	36
GO:007169212	Breast	IDC	protein localization to extracellular region	42/1434	368/18723	6.13e-03	4.38e-02	42
GO:000930613	Breast	IDC	protein secretion	41/1434	359/18723	6.64e-03	4.63e-02	41
GO:003559213	Breast	IDC	establishment of protein localization to extracellular region	41/1434	360/18723	6.96e-03	4.81e-02	41
GO:000645723	Breast	DCIS	protein folding	47/1390	212/18723	7.84e-12	1.53e-09	47
GO:004586123	Breast	DCIS	negative regulation of proteolysis	63/1390	351/18723	4.39e-11	6.06e-09	63
GO:000641724	Breast	DCIS	regulation of translation	72/1390	468/18723	2.46e-09	2.17e-07	72
GO:005070822	Breast	DCIS	regulation of protein secretion	35/1390	268/18723	7.83e-04	9.11e-03	35
GO:007169222	Breast	DCIS	protein localization to extracellular region	41/1390	368/18723	6.01e-03	4.29e-02	41
GO:000930622	Breast	DCIS	protein secretion	40/1390	359/18723	6.59e-03	4.61e-02	40
GO:003559222	Breast	DCIS	establishment of protein localization to extracellular region	40/1390	360/18723	6.90e-03	4.77e-02	40
GO:004603410	Cervix	CC	ATP metabolic process	90/2311	277/18723	7.90e-19	2.36e-15	90
GO:000611910	Cervix	CC	oxidative phosphorylation	55/2311	141/18723	7.12e-16	1.42e-12	55
GO:00090609	Cervix	CC	aerobic respiration	60/2311	189/18723	1.59e-12	6.36e-10	60
GO:00427739	Cervix	CC	ATP synthesis coupled electron transport	38/2311	95/18723	8.45e-12	2.66e-09	38
GO:00427759	Cervix	CC	mitochondrial ATP synthesis coupled electron transport	38/2311	95/18723	8.45e-12	2.66e-09	38
GO:00196469	Cervix	CC	aerobic electron transport chain	36/2311	87/18723	9.15e-12	2.74e-09	36

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50

Enriched KEGG pathways.

Pathway ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	qvalue	Count
hsa0414124	Breast	IDC	Protein processing in endoplasmic reticulum	36/867	174/8465	2.73e-05	2.86e-04	2.14e-04	36
hsa0414134	Breast	IDC	Protein processing in endoplasmic reticulum	36/867	174/8465	2.73e-05	2.86e-04	2.14e-04	36
hsa0414143	Breast	DCIS	Protein processing in endoplasmic reticulum	36/846	174/8465	1.60e-05	1.91e-04	1.41e-04	36
hsa0414153	Breast	DCIS	Protein processing in endoplasmic reticulum	36/846	174/8465	1.60e-05	1.91e-04	1.41e-04	36
hsa04141	Colorectum	AD	Protein processing in endoplasmic reticulum	80/2092	174/8465	5.96e-10	1.25e-08	7.96e-09	80
hsa041411	Colorectum	AD	Protein processing in endoplasmic reticulum	80/2092	174/8465	5.96e-10	1.25e-08	7.96e-09	80
hsa041414	Colorectum	MSS	Protein processing in endoplasmic reticulum	75/1875	174/8465	3.78e-10	8.44e-09	5.17e-09	75
hsa041415	Colorectum	MSS	Protein processing in endoplasmic reticulum	75/1875	174/8465	3.78e-10	8.44e-09	5.17e-09	75
hsa041418	Colorectum	FAP	Protein processing in endoplasmic reticulum	50/1404	174/8465	3.64e-05	3.68e-04	2.24e-04	50
hsa041419	Colorectum	FAP	Protein processing in endoplasmic reticulum	50/1404	174/8465	3.64e-05	3.68e-04	2.24e-04	50
hsa0414139	Esophagus	HGIN	Protein processing in endoplasmic reticulum	67/1383	174/8465	1.06e-12	2.16e-11	1.72e-11	67
hsa04141114	Esophagus	HGIN	Protein processing in endoplasmic reticulum	67/1383	174/8465	1.06e-12	2.16e-11	1.72e-11	67
hsa04141211	Esophagus	ESCC	Protein processing in endoplasmic reticulum	147/4205	174/8465	3.29e-22	1.10e-19	5.64e-20	147
hsa04141310	Esophagus	ESCC	Protein processing in endoplasmic reticulum	147/4205	174/8465	3.29e-22	1.10e-19	5.64e-20	147
hsa0414114	Liver	Cirrhotic	Protein processing in endoplasmic reticulum	114/2530	174/8465	1.16e-22	9.67e-21	5.96e-21	114
hsa0414115	Liver	Cirrhotic	Protein processing in endoplasmic reticulum	114/2530	174/8465	1.16e-22	9.67e-21	5.96e-21	114
hsa0414122	Liver	HCC	Protein processing in endoplasmic reticulum	146/4020	174/8465	7.34e-24	2.46e-21	1.37e-21	146
hsa0414132	Liver	HCC	Protein processing in endoplasmic reticulum	146/4020	174/8465	7.34e-24	2.46e-21	1.37e-21	146
hsa0414116	Lung	IAC	Protein processing in endoplasmic reticulum	37/1053	174/8465	6.53e-04	5.73e-03	3.81e-03	37
hsa0414117	Lung	IAC	Protein processing in endoplasmic reticulum	37/1053	174/8465	6.53e-04	5.73e-03	3.81e-03	37

Page: 1 2

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

DNAJC1

SNV

Missense_Mutation

c.869N>T

p.Pro290Leu

p.P290L

Q96KC8

protein_coding

deleterious(0.01)

benign(0.005)

TCGA-BH-A0HF-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Hormone Therapy

arimidex

DNAJC1

SNV

Missense_Mutation

c.1644N>C

p.Lys548Asn

p.K548N

Q96KC8

protein_coding

deleterious(0)

possibly_damaging(0.563)

TCGA-D8-A1JA-01

Breast

breast invasive carcinoma

Female

<65

III/IV

Chemotherapy

adriamycin

DNAJC1

insertion

Frame_Shift_Ins

novel

c.1285_1286insTGATGGGGAAAGAGGCCTCTGCACAGGTGTTAGAATCC

p.Asp429ValfsTer58

p.D429Vfs*58

Q96KC8

protein_coding

TCGA-A8-A07U-01

Breast

breast invasive carcinoma

Female

>=65

III/IV

Chemotherapy

5-fluorouracil

DNAJC1

SNV

Missense_Mutation

rs781526289

c.1333N>T

p.Arg445Trp

p.R445W

Q96KC8

protein_coding

deleterious(0)

probably_damaging(0.995)

TCGA-C5-A7CO-01

Cervix

cervical & endocervical cancer

Female

>=65

I/II

Chemotherapy

cisplatin

DNAJC1

SNV

Missense_Mutation

c.1252G>C

p.Glu418Gln

p.E418Q

Q96KC8

protein_coding

tolerated(0.25)

benign(0.005)

TCGA-DR-A0ZM-01

Cervix

cervical & endocervical cancer

Female

<65

III/IV

Unspecific

Cisplatin

DNAJC1

SNV

Missense_Mutation

c.1180N>C

p.Val394Leu

p.V394L

Q96KC8

protein_coding

tolerated(0.13)

benign(0.001)

TCGA-JW-A5VK-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Unknown

DNAJC1

SNV

Missense_Mutation

c.1466N>C

p.Arg489Thr

p.R489T

Q96KC8

protein_coding

tolerated(0.17)

benign(0.024)

TCGA-Q1-A73P-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Unknown

DNAJC1

SNV

Missense_Mutation

c.1225N>A

p.Asp409Asn

p.D409N

Q96KC8

protein_coding

tolerated(0.14)

benign(0.038)

TCGA-Q1-A73P-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Unknown

DNAJC1

SNV

Missense_Mutation

c.332N>T

p.Ala111Val

p.A111V

Q96KC8

protein_coding

deleterious(0)

probably_damaging(0.999)

TCGA-A6-6780-01

Colorectum

colon adenocarcinoma

Male

>=65

I/II

Unknown

DNAJC1

SNV

Missense_Mutation

c.1439G>T

p.Ser480Ile

p.S480I

Q96KC8

protein_coding

deleterious(0.03)

probably_damaging(0.994)

TCGA-AD-5900-01

Colorectum

colon adenocarcinoma

Male

>=65

I/II

Unknown

Page: 1 2 3 4 5 6

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID

Symbol

Category

Interaction Types

Drug Claim Name

Drug Name

PMIDs

Page: 1